TScan Therapeutics, Inc. Annual Report - A Year in Review

TScan Therapeutics, Inc. (Nasdaq: TCRX) released its annual report covering performance through December 31, 2025. This summary distills the key information, offering a clear picture of the company's progress and financial health for retail investors.

As a "smaller reporting company" and "emerging growth company," TScan operates in the early stages of its development. The company primarily focuses on research and development rather than commercializing established products. As of December 31, 2025, TScan's publicly traded stock held a market value of approximately $56.8 million.

Business Overview: Pioneering T-Cell Therapies

TScan Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing T cell receptor (TCR)-engineered T cell, or TCR-T, therapy. This advanced cell therapy harnesses a patient's own immune cells (T cells) to more effectively target and fight diseases like cancer.

Key Programs and Strategy

TScan's strategy centers on advancing its TCR-T therapies, with a clear focus:

• Lead Programs (Blood Cancers): The company's most advanced programs, TSC-100 and TSC-101, aim to prevent relapse in patients with blood cancers (hematologic malignancies) following a stem cell transplant. Both candidates are currently undergoing Phase 1 clinical trials, evaluating their safety and initial effectiveness in a small group of patients.
• Solid Tumor Programs: TScan also pursues earlier-stage programs targeting solid tumors, including those that target specific cancer markers like PRAME and MAGE-A1. These programs are generally in preclinical development.
• Strategic Prioritization: In November 2025, TScan strategically decided to prioritize its blood cancer (heme) programs, such as TSC-100 and TSC-101. This shift followed promising early data and a clearer path to market, leading the company to allocate more resources to these programs and potentially seek partnerships or de-prioritize some earlier-stage solid tumor efforts.
• Amgen Partnership: A significant collaboration with Amgen, initiated in mid-2023, provides both funding and validation for TScan's proprietary TCR discovery platform.

As an emerging company, TScan's primary objectives include:

• Developing New Treatments: Advancing lead candidates through rigorous clinical trials.
• Securing Regulatory Approvals: Obtaining necessary approvals from regulatory bodies to eventually commercialize new therapies.
• Building Commercial Capabilities: Establishing the infrastructure for manufacturing and selling therapies if approved.

Financial Performance: Year in Review (2025 vs. 2024)

Let's examine TScan's financial performance from 2024 to 2025.

1. Revenue (Money Coming In): TScan reported strong growth in collaboration and license revenue, generating approximately $10.3 million in 2025. This marks a substantial increase of over 260% from the $2.8 million earned in 2024. The boost primarily stemmed from the Amgen partnership, as TScan ramped up its joint research activities.

2. Operating Expenses (Costs to Run the Business): As a company heavily invested in research, TScan incurs significant costs to develop its treatments. Total operating expenses increased to approximately $146.1 million in 2025 from $137.6 million in 2024, an increase of about $8.5 million.

• Research and Development (R&D): R&D expenses, the largest component, rose by $6.8 million to $114.1 million in 2025. This increase primarily resulted from higher spending on lab supplies, research materials, and manufacturing activities (up $3.7 million), as well as increased facility costs (up $3.4 million) due to rent for an expansion space secured in late 2024. Personnel costs also increased by $2.2 million before the strategic shift in November 2025. Conversely, spending on clinical studies decreased by $2.4 million due to the timing of trial activities.
• General and Administrative (G&A): Costs for management, legal, and other administrative functions also increased slightly, rising by $1.7 million to $32.0 million in 2025. This was mainly driven by higher personnel and facility-related costs.

3. Net Loss (The Bottom Line): Due to expenses growing faster than revenue, TScan's net loss widened slightly. The company reported a net loss of approximately $129.8 million in 2025, compared to a loss of $127.5 million in 2024. This was also influenced by a $3.2 million decrease in interest income, as the company had less cash to invest. However, TScan benefited from lower interest expenses and avoided a one-time debt charge incurred in 2024.

Risk Factors

TScan operates in a cutting-edge field, and its success is subject to significant risks. The company highlights several critical factors that could impact its future:

• Clinical Trial Success: A primary risk is whether lead candidates, TSC-100 and TSC-101, will demonstrate sufficient safety and efficacy in ongoing and future clinical trials. Most experimental therapies do not succeed in clinical development.
• Regulatory Approval: Obtaining regulatory approval for novel cell therapies is a complex and lengthy process, presenting a significant hurdle due to unique manufacturing and safety considerations.
• Intense Competition: TScan faces fierce competition from other companies developing TCR-T therapies, CAR-T therapies, and various immuno-oncology treatments. Many competitors are larger and possess greater resources.
• Intellectual Property (IP) Protection: Protecting its proprietary TCR discovery platform and specific TCR sequences from infringement is vital for long-term success.
• Manufacturing Challenges: Developing and scaling up the manufacturing of complex, personalized cell therapies like TCR-T therapies is technically demanding and costly.
• Reliance on Partnerships: TScan's dependence on key collaborations, particularly with Amgen, for funding and development expertise means that any changes to these agreements could significantly impact its operations.
• Need for Future Funding: TScan will require substantial additional capital to fund its extensive research and development activities. This could lead to shareholder dilution (reducing existing ownership percentages) or increased debt.

Financial Health: Debt, Cash, and Liquidity

As TScan does not yet generate revenue from product sales, it relies heavily on external funding to support its research.

• Cash on Hand: As of December 31, 2025, TScan held approximately $152.4 million in cash and cash equivalents.
• Capital Raising Activities: The company has actively raised capital. In 2024 alone, TScan generated a significant $208.8 million through public stock offerings and new loans. In 2023, it received a $30 million upfront payment from the Amgen partnership and raised another $134.7 million from a stock offering. TScan also restructured its debt, converting part of an older loan into stock and securing a new loan agreement with SVB in late 2024.
• Cash Flow - Where the Money Went:
  • Operating Activities: TScan utilized approximately $135.3 million for its day-to-day operations in 2025, a notable increase from the $110.8 million used in 2024. This reflects increased spending to sustain business operations and fund research.
  • Investing Activities: In 2025, TScan generated $109.4 million from investing activities, primarily through managing its marketable securities (e.g., short-term investments). This contrasts sharply with 2024, when it used $52.6 million in investing activities.
  • Financing Activities: This category saw the most significant change. In 2024, TScan generated $208.8 million from financing (issuing stock, securing loans). In 2025, however, it utilized a small amount, approximately $0.3 million, for financing. This indicates that substantial fundraising in 2024 built cash reserves that supported operations and investments in 2025.
  • Overall Cash Change: TScan's cash balance decreased by $26.3 million in 2025, following an increase of $45.3 million in 2024. This shift reflects the heavy capital raising in 2024 that subsequently funded operations and investments in 2025.

Future Outlook

• Cash Runway: TScan projects its current cash will fund operations and research needs into the second half of 2027. However, the company explicitly states this estimate could prove inaccurate, and it may consume cash faster than anticipated.
• Need for Additional Funding: TScan expects expenses to continue increasing as it advances treatments through further research and clinical trials. This necessitates raising additional capital in the future, likely through issuing more stock (which could dilute existing shares) or incurring more debt (potentially with operational restrictions). The company does not foresee generating revenue from product sales for several more years, if at all, and anticipates continued significant losses.
• Strategic Focus: The November 2025 decision to prioritize blood cancer (heme) programs (TSC-100 and TSC-101) forms a key part of TScan's future strategy. This aims to accelerate development in areas with promising early data and a clearer path to market. Continued collaboration with Amgen also remains central to its long-term plans.

Competitive Position

TScan operates within the highly competitive and rapidly evolving cell therapy and immuno-oncology landscape. Its primary competitors include:

• Other TCR-T Therapy Developers: Companies pursuing similar T cell receptor-engineered T cell approaches.
• CAR-T Therapy Developers: Companies developing Chimeric Antigen Receptor (CAR)-T cell therapies, a more established form of cell therapy for blood cancers.
• Other Immuno-Oncology Companies: A broad range of pharmaceutical and biotechnology companies developing diverse cancer immunotherapies, such as checkpoint inhibitors, oncolytic viruses, and bispecific antibodies.

Many of these competitors are significantly larger, possess greater financial, technical, and human resources, and have more extensive experience in drug development, clinical trials, manufacturing, and commercialization.

TScan aims to differentiate itself through:

• Proprietary TCR Discovery Platform: Its unique platform for identifying novel and highly potent TCRs represents a key competitive advantage.
• Specific Target Selection: Focusing on specific targets for blood cancers (e.g., preventing relapse post-transplant) and certain solid tumor markers (PRAME, MAGE-A1) allows TScan to carve out specific niches.
• Strategic Partnerships: Collaborations, such as the one with Amgen, provide validation, resources, and expertise that enhance TScan's competitive standing.

Demonstrating superior efficacy and safety in clinical trials, securing regulatory approvals, protecting intellectual property, and efficiently manufacturing its complex therapies will be critical for TScan to establish and maintain a competitive position.

In summary, TScan is successfully growing its collaboration revenue but remains deeply in the R&D phase, leading to increasing expenses and continued losses. The company has effectively raised significant capital to fund its operations and expects its current cash to last into the second half of 2027, though further funding will be necessary thereafter. Its strategic focus on lead blood cancer programs, TSC-100 and TSC-101, will be pivotal for future progress within a highly competitive landscape. Investors should weigh the significant potential of its innovative T-cell therapies against the inherent risks of clinical development, intense competition, and the ongoing need for substantial capital.